# Jcm Ho

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jcm-ho/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,837 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 50 |
| i10-index | 185 |
| Last Known Institution | Chinese University of Hong Kong |
| OpenAlex ID | https://openalex.org/A5030417585 |
| ORCID iD | 0000-0003-4499-5284 |
| Works | 536 |

## Researcher papers

- [Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/ramucirumab-plus-erlotinib-in-patients-with-untreated-egfr-mutated-advanced-non/)
- [Impact of EGFR Inhibitor in Non–Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis](https://scholariq.org/papers/impact-of-egfr-inhibitor-in-non-small-cell-lung-cancer-on-progression-free-and/)
- [Severe Acute Respiratory Syndrome: Temporal Lung Changes at Thin-Section CT in 30 Patients](https://scholariq.org/papers/severe-acute-respiratory-syndrome-temporal-lung-changes-at-thin-section-ct-in-30/)
- [The Effect of Aging on Nasal Mucociliary Clearance, Beat Frequency, and Ultrastructure of Respiratory Cilia](https://scholariq.org/papers/the-effect-of-aging-on-nasal-mucociliary-clearance-beat-frequency-and/)
- [A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas](https://scholariq.org/papers/a-phase-ii-clinical-and-pharmacodynamic-study-of-temsirolimus-in-advanced/)
- [Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial](https://scholariq.org/papers/intercalated-combination-of-chemotherapy-and-erlotinib-for-patients-with/)
- [Differential expression of manganese superoxide dismutase and catalase in lung cancer.](https://scholariq.org/papers/differential-expression-of-manganese-superoxide-dismutase-and-catalase-in-lung/)
- [Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands](https://scholariq.org/papers/phase-ii-study-of-lapatinib-in-recurrent-or-metastatic-epidermal-growth-factor/)
- [Evaluation of Pulmonary Nodules](https://scholariq.org/papers/evaluation-of-pulmonary-nodules/)
- [High–Dose Pulse Versus Nonpulse Corticosteroid Regimens in Severe Acute Respiratory Syndrome](https://scholariq.org/papers/high-dose-pulse-versus-nonpulse-corticosteroid-regimens-in-severe-acute/)
- [Genetic alterations and cellular properties of acquired arsenic resistance in small cell lung cancer](https://scholariq.org/papers/genetic-alterations-and-cellular-properties-of-acquired-arsenic-resistance-in/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cystic Fibrosis Research Advances](https://scholariq.org/topics/cystic-fibrosis-research-advances/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Chronic Obstructive Pulmonary Disease (COPD) Research](https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/)

## Researcher university

- [Chinese University of Hong Kong](https://scholariq.org/institutions/chinese-university-of-hong-kong/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.